Share on StockTwits
 

Equities researchers at Deutsche Bank upped their target price on shares of BTG (LON:BTG) from GBX 610 ($10.01) to GBX 635 ($10.42) in a research report issued on Friday, Stock Ratings Network.com reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s target price suggests a potential upside of 6.54% from the stock’s previous close.

BTG (LON:BTG) traded down 1.32% during mid-day trading on Friday, hitting GBX 596.00. 867,626 shares of the company’s stock traded hands. BTG has a 52 week low of GBX 313.70 and a 52 week high of GBX 624.00. The stock has a 50-day moving average of GBX 580.1 and a 200-day moving average of GBX 449.0.

BTG has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of BTG in a research note to investors on Tuesday, January 14th. They now have a GBX 630 ($10.34) price target on the stock. Finally, analysts at N+1 Singer reiterated a “sell” rating on shares of BTG in a research note to investors on Thursday, January 2nd. They now have a GBX 490 ($8.04) price target on the stock. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. BTG has an average rating of “Hold” and an average target price of GBX 547.25 ($8.98).

BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.